Fig. 5

a Representative Western blot images of TLR4 in the control group and the agomir treatment group at day 3, week 1, week 2 and week 4 after pilocarpine-induced SE. b Quantification of immunoblot intensity in (a) (*P < 0.05 versus control group; n  =  4 per group). c Representative Western blot images of TLR4 in the control group and the antagomir treatment group at day 3, week 1, week 2 and week 4 after pilocarpine-induced SE. d Quantification of immunoblot intensity in (c) (*P < 0.05 versus control group; n  =  4 per group). e Behavior analysis of pilocarpine-induced SE showed that the degree of seizures in the antagomir group at various time points (10 min, 20 min, 30 min) was significantly higher than that of the vehicle group, while this increase was reversed in the antagomir + TAK-242 group. f The latency to SE in the antagomir group, antagomir+TAK-242 group and vehicle group (*P < 0.05 versus vehicle group; n  = 8 per group). g Representative Western blots of TLR4 in the different groups. h Quantification results showed that the antagomir increased the expression of both IL-6 and TNF-α, whereas this increase was reversed in the antagomir+TAK-242 group (*P < 0.05 versus vehicle group; n = 8 per group)